Lagevrio 200 mg

(Molnupiravir)

The antiviral is indicated for the treatment of mild to moderate disease of COVID-19 (caused by SARS-CoV-2) in adults who are at risk of developing severe disease. It can help avoid hospitalization. The condition is at least one risk factor for the development of a serious disease (e.g. a person older than 18 years, positive test for SARS-CoV-2: antigenic or PCR, the patient's clinical condition does not require hospitalization and therapeutic oxygen administration for COVID-19, chronic onem. etc. ).

How to take the medicine

The recommended dose is 800 mg (four 200 mg capsules) taken orally every 12 hours for 5 days. Lagevrio must be started as soon as possible after the diagnosis of COVID-19 and within 5 days of the onset of symptoms. The capsules must be swallowed whole (do not break or crush) and drink with a sufficient amount of liquid. Can be taken with or without food.

A voucher for the provision of the product will be issued by a general practitioner or other outpatient specialist based on a clinical examination of the patient.

LAGEVRIO (Molnupiravir) can be picked up at the VFN main pharmacy - U Nemocnice 499/2.

The medicine will be issued upon presentation of document 06 - voucher for examination/treatment completed by a doctor.

Paxlovid 150 mg + 100 mg

It contains separate tablets of two active substances: PF-07321332 (nirmatrelvir) and ritonavir.

The antiviral is intended for the treatment of the disease COVID-19 in adults who do not require additional oxygen treatment and who are at increased risk of a severe course of the disease.

Treatment with Paxlovid may reduce hospitalization rates in patients with COVID-19.

How to take the medicine

The recommended dose is two (pink) tablets containing 150 mg nirmatrelvir and one (white) tablet containing 100 mg ritonavir taken orally every 12 hours for 5 days. Paxlovid should be given as soon as possible after a diagnosis of COVID-19 is made and no later than 5 days after the onset of symptoms of COVID-19.

Can be taken with or without food. Tablets must be swallowed whole (do not divide, do not crush).

The medicinal product Paxlovid can only be provided to the patient on the basis of document 06 (voucher for examination/treatment) issued by the referring physician based on the clinical examination of the patient. On document 06, the referring physician states the justification for the request to provide the medicinal product to the patient.

The condition for performance reporting is the entry of information about the provision of the medicinal product to the patient in the ISIN (Infectious Diseases Information System).

Both preparations have numerous drug interactions, which must always be checked in the SPC before starting treatment and, if necessary, adjust other medications. Used sources: https://www.sukl.cz and https://www.ema.europa.eu